VolitionRx Limited Initiates Study with Hvidovre Hospital, Denmark, Specifically to Target NuQ(R) Biomarker Panel for Colorectal Polyps
Apr 21 15
VolitionRx Limited announced that Hvidovre Hospital, University of Copenhagen, Denmark has initiated a study specifically to identify a NuQ® biomarker panel for the identification of patients with precancerous colorectal polyps particularly those that are at high risk of becoming cancers. In the study, a set of approximately 800 blinded prospectively-collected blood samples will be analyzed, including: 300 patients with single or multiple precancerous polyp(s) (including approximately 100 patients whose polyps subsequently recurred after removal); 400 subjects with no polyps or colorectal cancers (both with and without other diseases); plus 100 early stage (I/II) colorectal cancer patients. The cohort will comprise high and low risk polyps of various histologies. Following collection, the samples will be analyzed by VolitionRx using up to 30 NuQ® assays.
VolitionRx Limited Adds Three New Laboratory Automation Systems to Expedite Sample Analysis
Apr 9 15
VolitionRx Limited announced that it has procured three additional Tecan EVO200  automated liquid handling systems (automated laboratory robots) to expedite analysis of samples for the ongoing large clinical trials evaluating its NuQ® cancer detection platform. By increasing capacity to four automated systems, throughput and rate of sample analysis will be greatly increased, enabling faster development of the company's NuQ® tests. Using its first installed robot, VolitionRx has recently completed the analysis of a first NuQ® assay on the complete set of 4,800 blood samples for its large retrospective, symptomatic population colorectal cancer study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark. Procuring three new Tecans allows the Company to dedicate one robot to this study, and VolitionRx now hopes to complete one NuQ® assay per month on the full data set for the 4,800-patient cohort. At this capacity, the company expects to finalize its analysis and determine an initial NuQ® colorectal cancer panel during the second half of 2015. The NuQ® tests utilize the Company's proprietary Nucleosomics® technology platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals within the blood. VolitionRx has developed a suite of NuQ® assays for more than 20 different epigenetic structures on nucleosomes. These assays use two antibodies. The first antibody is attached to a plastic surface and binds to nucleosomes. The second antibody is chemically detectable and binds to the epigenetic structure of interest contained within the nucleosome. When blood is added to the antibody-coated plastic plate, nucleosomes in the blood bind to the first antibody. The second antibody is then added and can only be chemically detected if nucleosomes containing the epigenetic structure of interest are present. The NuQ® assay uses less than a single drop of blood to measure nucleosomes that contain the epigenetic structure of interest and the level of these nucleosomes is different in the blood of cancer patients than in healthy people. Each NuQ® cancer test uses a combination of 4-5 of these proprietary assays to form a 'panel' test. Clinical trials assessing the effectiveness of VolitionRx's assays include: Colorectal cancer: A 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark). A 14,000 patient prospective screening study (Hvidovre Hospital, University of Copenhagen, Denmark). A 250 patient prospective study (CHU-UCL Mont Godinne Hospital, Belgium). Lung cancer: A 600 patient prospective confirmatory study (University Hospital, Bonn, Germany). Prostate cancer: A retrospective study to establish the efficacy of VolitionRx's NuQ® tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form (MD Anderson, Texas). A 120-patient prospective feasibility study (ImmuneHealth, Belgium). Ovarian cancer: A 40-patient prospective feasibility study (Singapore General Hospital, Singapore). 20 most prevalent cancers: A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany. Endometriosis: A prospective study to assess VolitionRx's NuQ® tests for the diagnosis of endometriosis (the University of Oxford, United Kingdom).
VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology
Mar 5 15
VolitionRx Limited announced that it has initiated a pilot study to assess the feasibility of VolitionRx's proprietary NuQ® assays in detecting prostate cancer. The study is in collaboration with ImmuneHealth and is taking place in Belgium. In the prospective study, 120 blood samples will be collected from patients across four Belgian hospitals and analyzed by Belgium-based ImmuneHealth using VolitionRx's NuQ® assays, which are based on the Company's proprietary Nucleosomics® technology. Four groups of patients will be assessed: aggressive prostate cancer, indolent prostate cancer, prostate hyperplasia and negative controls. In addition to determining the test's ability to accurately detect prostate cancer, the study will also assess the tests' ability to distinguish among the different prostate conditions and healthy samples. If the test demonstrates significant accuracy, it could have the potential to become an early-stage screening tool.